- Home
- LCFY vs RNAZ Comparison
LCFY vs RNAZ Comparison
Compare LCFY & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LCFY | RNAZ |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | Australia | United States |
| Employees | 18 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 8.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LCFY | RNAZ |
|---|---|---|
| Price | $4.20 | $8.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $280.00 |
| AVG Volume (30 Days) | ★ 13.6K | 7.2K |
| Earning Date | 03-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $0.22 |
| 52 Week High | $13.98 | $20.99 |
Technical Indicators
Market Signals| Indicator | LCFY | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 50.06 | 42.19 |
| Support Level | $4.07 | $8.37 |
| Resistance Level | $4.80 | $11.62 |
| Average True Range (ATR) | 0.24 | 0.49 |
| MACD | -0.07 | -0.09 |
| Stochastic Oscillator | 31.37 | 19.99 |
Price Performance
Historical ComparisonAbout LCFY Locafy Limited
Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.